BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly’s tirzepatide for the treatment of obesity.
The drug developer decided to stop the trial after liver transaminitis, or high levels of certain liver enzymes, were observed in patients receiving the experimental drug, azelaprag.
Tirzepatide is the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound.
The mid-stage trial enrolled about 220 individuals with obesity aged 55 years and older.
BioAge discontinues mid-stage trial of obesity drug
Date:
More like thisRelated
AI-powered Fallout recap removed from Prime Video after users flag errors
Amazon has removed an AI-generated video recap...
First date to their dream trip; INSIDE Tara Sutaria and Veer Pahariya’s love story |
Tara Sutaria and Veer Pahariya confirmed their relationship...
Boomers stay late, Millennials burn out, GenZ set boundaries: Welcome to work life in 2025 | India News
Walk into any corporate office today, and...
Anushka Sharma returns to India, spotted with Virat Kohli at Mumbai airport |
Anushka Sharma was spotted in Mumbai with Virat...